Tag: GeNeuro
Geneuro obtains a compositional reprieve
[ad_1] (AOF) – Geneuro (+5.15% to 0.08 euro) announces that the Court of First Instance of Geneva has approved its request for a debt restructuring suspension of July 15, 2024,…
GeNeuro SA obtains the opening of a compositional suspension procedure – 09/30/2024 at 07:00
[ad_1] Geneva, Switzerland, September 30, 2024 – 7:00 a.m. CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that…
GeNeuro – Presentation of new data at ECTRIMS 2025 in Copenhagen showing the repair of neurodegenerative effects of HERV-W by Temelimab in a model of MS – 09/19/2024 at 6:30 p.m.
[ad_1] Geneva, Switzerland, September 19, 2024 – 6:30 PM CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on addressing the drivers of neurodegenerative and autoimmune diseases,…
GeNeuro: request for a stay of execution to restructure its debts
[ad_1] By Arnaud Bives Published on 07/15/2024 at 07:59 (Boursier.com) — GeNeuro announces that it is filing today with the Geneva…
Geneuro: request for a stay of execution after the failure of the GNC-501 trial – 07/15/2024 at 09:57
[ad_1] (AOF) – GeNeuro announces that it is filing today with the Geneva Court of First Instance a request for a “concordat stay” to restructure its debts and find solutions…
Geneuro: request for a stay of execution following the failure of the GNC-501 trial
[ad_1] (AOF) – GeNeuro announces that it is filing today with the Geneva Court of First Instance a request for a “concordat stay” to restructure its debts and find solutions…
GeNeuro: a procedure to restructure the debt – 07/15/2024 at 11:56
[ad_1] (CercleFinance.com) – GeNeuro announced on Monday that it had filed a request for a stay of composition with the Geneva Court of First Instance in order to restructure its…
GeNeuro announces filing of a request for a stay of composition at the Geneva Court of First Instance – 07/15/2024 at 07:00
[ad_1] GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe…
GeNeuro: failure of the GNC-501 trial in post-Covid-19 syndrome
[ad_1] By Arnaud Bives Published on 06/28/2024 at 07:49 (Boursier.com) — GeNeuro announces this morning the results of the GNC-501 trialin…
GeNeuro shareholders approve all resolutions proposed at the 2024 Annual General Meeting – 06/14/2024 at 6:30 p.m.
[ad_1] GeNeuro shareholders approve all resolutions proposed at the 2024 Annual General Meeting 81.54% of the company’s share capital was represented at the general meeting and the resolutions were all…
GeNeuro – Conditions for providing information relating to the general meeting of shareholders of June 12, 2024 – 05/29/2024 at 7:30 p.m.
[ad_1] Geneva, Switzerland, May 29, 2024 – 7:00 p.m. CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple…
GeNeuro: The cash position was 2.8 ME as of December 31
[ad_1] By Claude Leguilloux Published on 02/05/2024 at 07:03 a.m. Photo credit © ChaunuPictures (Boursier.com) — GeNeuro…